New research from the IU School of Medicine found a discovery that could lead to new treatments for prostate cancer. The ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...

Medical advancements make early-detected cancers more manageable and treatable, with immunotherapy and CAR T cell therapy ...

Overall, PSMA-PET/CT detected distant metastasis in 84 of 182 cases (46%) that were negative by other types of imaging, ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

HRS-1167 is under clinical development by Merck and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC).

Request To Download Free Sample of This Strategic Report @ This country research report on Vietnam Prostate Cancer Therapeutics Market offers comprehensive insights into the market landscape, ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.

Low testosterone (hypogonadism) is a condition where your body doesn’t produce enough of the hormone. It has several possible ...

Advanced imaging reveals hidden metastases in high-risk prostate cancer cases, offering new insights for better diagnosis and treatment strategies.